Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 99.4% in March

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 137,200 shares, a growth of 99.4% from the March 15th total of 68,800 shares. Approximately 3.1% of the company’s stock are sold short. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is currently 0.1 days.

Vincerx Pharma Trading Up 6.6 %

Shares of NASDAQ:VINC opened at $0.27 on Thursday. Vincerx Pharma has a 52 week low of $0.22 and a 52 week high of $19.88. The company’s 50 day moving average is $0.79 and its two-hundred day moving average is $3.88. The company has a market cap of $1.43 million, a PE ratio of -0.01 and a beta of 1.67.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.